NN 9030

Drug Profile

NN 9030

Alternative Names: G-530-L; G530 S; NN-9030; NNC9204-0530

Latest Information Update: 03 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Novo Nordisk
  • Class Obesity therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Obesity

Most Recent Events

  • 07 Jul 2017 Novo Nordisk completes a phase I trial for Obesity in USA (SC) (NCT02835235)
  • 16 Dec 2016 Biomarkers information updated
  • 01 Aug 2016 Novo Nordisk initiates a phase I trial for Obesity (Combination therapy) in USA (SC) (NCT02870231)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top